|
gptkbp:instanceOf
|
anticoagulant medication
|
|
gptkbp:antidote
|
gptkb:idarucizumab
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
3-7%
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:contraindication
|
active pathological bleeding
mechanical prosthetic heart valve
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
capsule
|
|
gptkbp:genericName
|
dabigatran etexilate
|
|
gptkbp:halfLife
|
12-17 hours
|
|
gptkbp:hasBoxedWarning
|
risk of spinal/epidural hematoma
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pradaxa
|
|
gptkbp:indication
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:mechanismOfAction
|
direct thrombin inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:riskFactor
|
increased risk of bleeding with concomitant use of other anticoagulants
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
gastrointestinal upset
|
|
gptkbp:bfsParent
|
gptkb:Boehringer_Ingelheim
gptkb:DB09054
gptkb:DB12023
gptkb:dabigatran
|
|
gptkbp:bfsLayer
|
6
|